Neurocrine Biosciences (NBIX) Upgraded at ValuEngine

ValuEngine upgraded shares of Neurocrine Biosciences (NASDAQ:NBIX) from a buy rating to a strong-buy rating in a research note released on Monday.

A number of other equities analysts have also weighed in on NBIX. Deutsche Bank set a $99.00 price target on Neurocrine Biosciences and gave the company a buy rating in a research report on Tuesday, May 1st. Oppenheimer set a $120.00 price target on Neurocrine Biosciences and gave the company a buy rating in a research report on Monday. BidaskClub upgraded Neurocrine Biosciences from a hold rating to a buy rating in a research report on Wednesday, May 9th. Bank of America increased their price target on Neurocrine Biosciences from $101.00 to $102.00 and gave the company a buy rating in a research report on Tuesday, May 1st. Finally, Cowen reiterated a buy rating and issued a $100.00 price target on shares of Neurocrine Biosciences in a research report on Monday, May 7th. Thirteen equities research analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the company’s stock. The company presently has a consensus rating of Buy and an average target price of $102.77.

Shares of Neurocrine Biosciences traded down $0.51, reaching $91.98, during midday trading on Monday, Marketbeat reports. The company had a trading volume of 5,884 shares, compared to its average volume of 869,202. The company has a current ratio of 11.06, a quick ratio of 11.06 and a debt-to-equity ratio of 1.03. Neurocrine Biosciences has a 1-year low of $92.60 and a 1-year high of $94.19.

Neurocrine Biosciences (NASDAQ:NBIX) last released its quarterly earnings results on Monday, April 30th. The company reported ($0.47) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.29) by ($0.18). Neurocrine Biosciences had a negative net margin of 45.56% and a negative return on equity of 29.67%. The company had revenue of $71.08 million during the quarter, compared to analyst estimates of $65.17 million. During the same quarter last year, the business earned ($0.90) EPS. sell-side analysts anticipate that Neurocrine Biosciences will post -0.24 EPS for the current year.

In related news, Director Corinne H. Nevinny sold 5,000 shares of the stock in a transaction dated Monday, May 7th. The stock was sold at an average price of $83.13, for a total value of $415,650.00. Following the completion of the sale, the director now directly owns 43,283 shares of the company’s stock, valued at approximately $3,598,115.79. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, insider Haig P. Bozigian sold 75,873 shares of the stock in a transaction dated Monday, March 5th. The stock was sold at an average price of $90.00, for a total value of $6,828,570.00. Following the completion of the sale, the insider now directly owns 18,041 shares of the company’s stock, valued at $1,623,690. The disclosure for this sale can be found here. Over the last three months, insiders sold 207,705 shares of company stock valued at $17,485,904. Company insiders own 4.30% of the company’s stock.

A number of institutional investors have recently made changes to their positions in NBIX. American International Group Inc. purchased a new stake in shares of Neurocrine Biosciences during the 4th quarter worth about $161,000. Ladenburg Thalmann Financial Services Inc. raised its stake in shares of Neurocrine Biosciences by 103.4% during the 1st quarter. Ladenburg Thalmann Financial Services Inc. now owns 2,016 shares of the company’s stock worth $167,000 after purchasing an additional 1,025 shares in the last quarter. M&T Bank Corp purchased a new stake in shares of Neurocrine Biosciences during the 4th quarter worth about $202,000. GSA Capital Partners LLP purchased a new stake in shares of Neurocrine Biosciences during the 1st quarter worth about $202,000. Finally, Mission Wealth Management LP purchased a new stake in shares of Neurocrine Biosciences during the 4th quarter worth about $204,000.

Neurocrine Biosciences Company Profile

Neurocrine Biosciences, Inc discovers and develops pharmaceuticals for the treatment of neurological and endocrine-related diseases and disorders in the United States. The company's lead products include INGREZZA (valbenazine), a vesicular monoamine transporter 2 inhibitor (VMAT2), which is used for the treatment of movement disorders; elagolix, a gonadotropin-releasing hormone (GnRH) antagonist that is in Phase III clinical trial for use in women's health; and opicapone, a catechol-O-methyltransferase inhibitor, which is in Phase III clinical trial that is used for in adjunct therapy and preparations of levodopa/DOPA decarboxylase inhibitors for adult patients with Parkinson's disease.

To view ValuEngine’s full report, visit ValuEngine’s official website.

Analyst Recommendations for Neurocrine Biosciences (NASDAQ:NBIX)

Receive News & Ratings for Neurocrine Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neurocrine Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply